Kintor Pharmaceutical Ltd
HKEX:9939
Intrinsic Value
Kintor Pharmaceutical Ltd. is a clinical-stage novel drug developer in China, which focuses on the proprietary research and development of innovative medicine products for cancers and other Androgen r... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of Kintor Pharmaceutical Ltd.
Kintor Pharmaceutical Ltd's market capitalization is 420.6m HKD.
Kintor Pharmaceutical Ltd stock price is 0.94 HKD.
Kintor Pharmaceutical Ltd.
Kintor Pharmaceutical Ltd. Open DCF Valuation
Kintor Pharmaceutical Ltd. Open Relative Valuation
Kintor Pharmaceutical Ltd.
Kintor Pharmaceutical Ltd has negative Gross Profit for the last twelve months.
Kintor Pharmaceutical Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from -34% to -109%, and is approaching profitability.
Kintor Pharmaceutical Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -86% to -152%, and is approaching profitability.
Kintor Pharmaceutical Ltd's short-term assets (473m CNY) exceed its short-term liabilties (225m CNY).
Kintor Pharmaceutical Ltd's long-term assets (869m CNY) exceed its long-term liabilties (411m CNY).
Kintor Pharmaceutical Ltd has negative Operating Income for the last twelve months.
Kintor Pharmaceutical Ltd has negative Net Income for the last twelve months.
Kintor Pharmaceutical Ltd's ROE (Return on Equity) for the past 12 months is negative and is equal to -109%.
Kintor Pharmaceutical Ltd's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -152%.
Kintor Pharmaceutical Ltd's D/E (Debt to Equity) is very low and is equal to 0.3.
Kintor Pharmaceutical Ltd has negative Free Cash Flow for the last twelve months.
Kintor Pharmaceutical Ltd has negative Net Debt. This means that the company has more cash and short-term investments (456m CNY) than debt (136m CNY).
Kintor Pharmaceutical Ltd has negative three-year average ROE (Return on Equity): -57%. The company is not efficient at transforming stockholders' equity into net income.
Kintor Pharmaceutical Ltd has negative three-year average ROIC (Return on Invested Capital): -108%. The company is not efficient at using invested capital to generate operating income.
Kintor Pharmaceutical Ltd's Altman Z-Score is very low and is equal to -2.51.
Kintor Pharmaceutical Ltd doesn't generate enough operating income (-1B CNY) to safely cover interest payments on its debt (11m CNY).
Fundamental Analysis
Kintor Pharmaceutical Ltd
Balance Sheet Decomposition
Kintor Pharmaceutical Ltd
| Current Assets | 472.6m |
| Cash & Short-Term Investments | 456.3m |
| Receivables | 15.8m |
| Other Current Assets | 425k |
| Non-Current Assets | 396.7m |
| Long-Term Investments | 18m |
| PP&E | 221.8m |
| Intangibles | 148.9m |
| Other Non-Current Assets | 7.9m |
| Current Liabilities | 224.7m |
| Accounts Payable | 104.5m |
| Other Current Liabilities | 120.2m |
| Non-Current Liabilities | 186.4m |
| Long-Term Debt | 135.7m |
| Other Non-Current Liabilities | 50.7m |
Earnings Waterfall
Kintor Pharmaceutical Ltd
|
Revenue
|
0
CNY
|
|
Cost of Revenue
|
-42.2m
CNY
|
|
Gross Profit
|
-42.2m
CNY
|
|
Operating Expenses
|
-1B
CNY
|
|
Operating Income
|
-1.1B
CNY
|
|
Other Expenses
|
-1.1m
CNY
|
|
Net Income
|
-1.1B
CNY
|
Free Cash Flow Analysis
Kintor Pharmaceutical Ltd
Profitability Score
Profitability Due Diligence
Kintor Pharmaceutical Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Kintor Pharmaceutical Ltd's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Kintor Pharmaceutical Ltd's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Kintor Pharmaceutical Ltd's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Kintor Pharmaceutical Ltd
Shareholder Return
Price
Kintor Pharmaceutical Ltd
| Average Annual Return | -15.01% |
| Standard Deviation of Annual Returns | 42.28% |
| Max Drawdown | -99% |
| Market Capitalization | 420.6m HKD |
| Shares Outstanding | 435 288 512 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Kintor Pharmaceutical Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Kintor Pharmaceutical Ltd. is a clinical-stage novel drug developer in China, which focuses on the proprietary research and development of innovative medicine products for cancers and other Androgen receptor-related diseases. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-05-22. The firm is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The firm are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.
You don't have any saved screeners yet
